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Mitochondria are highly dynamic organelles exhibiting an elaborate morphology and fine structure. Fusion and fission processes contribute to
the maintenance and dynamics of mitochondrial morphology. The Mitofusins, a class of evolutionary conserved GTPases of the mitochondrial
outer membrane, are essential for the controlled fusion of mitochondrial membranes. Genetic and biochemical data propose a model in which
functional domains, such as the GTPase domain and the C-terminally located coiled coil structure, act in an orchestrated manner to coordinate the
tethering and mitochondrial outer membrane fusion. In addition, recent reports shed new light on the physiological importance of Mitofusin
function suggesting a role in mitochondrial metabolism, apoptosis as well as cellular signalling. Mutations identified in the human Mfn2 gene
from patients with the peripheral neuropathy Charcot–Marie–Tooth Type 2A invoke a direct correlation between mitochondrial morphology and
function.
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Mitochondria, the main organelles for cellular energy supply
and metabolism, participate in a variety of cellular processes
critical for cell function and organismal development, health
and aging, and also play key roles in programmed cell death. In
addition, mitochondria carry out the essential biochemical
pathways of amino acid asynthesis, steroid metabolism, fatty
acid oxidation and calcium homeostasis as well as iron
metabolism. An emerging concept in eukaryotic biology is
that the tissue-specific function and physiology of a eukaryotic
cell may depend on morphological changes and the differen-
tiation of its organelles. Mitochondria provide an excellent
example for studying distinct morphological changes accom-
panying relevant cellular function. These organelles undergo
certain differentiation steps to obtain a specialized mitochon-
drial membrane topology complying with the physiological
demands of the cell.
Mitochondria differ in their overall morphology from cell
type to cell type in size and structure. With respect to its fine⁎ Tel.: +49 30 9489 2832; fax: +49 30 9489 2801.
E-mail address: santel@atugen.com.
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.02.004structure the mitochondrial inner membrane (IM) invagina-
tions differ in a distinct manner among mitochondria and can
change in a flexible manner in response to intra- and extra-
cellular conditions or stimuli (for example [1,2]). Accord-
ingly, the mitochondrial IM exhibits structures such as the
lamellar, tubular or prismatic organization of mitochondrial
cristae [3–5]. Moreover, mitochondria have been shown to
reside as dynamic organelles within the cells. Even in a
single eukaryotic cell, mitochondria can constantly change
their localization, shape, and number. The structural basis of
mitochondrial morphogenesis is excellently illustrated during
Drosophila spermatogenesis, where the mitochondria under-
go a dramatic subcellular differentiation program that gives
rise to two structurally divergent mitochondrial derivates
(minor and major mitochondrial derivates) per sperm cell
[6,7].
The first clue to how mitochondrial dynamics is controlled
arose from the discovery of controlled mitochondrial fusion
events through a novel class of evolutionary conserved nuclear
encoded GTPases, known as the Mitofusins/Fzo proteins. The
founding member of this protein family, the Drosophila Fuzzy
onions protein, Fzo, is the first known protein mediator of
mitochondrial fusion [8]. In fuzzy onions (fzo) mutant males
Fig. 1. Schematic drawing summarizing conserved Fzo/Mitofusin protein family structures and domain functions.
Fig. 2. The human Mfn2 protein promotes mitochondrial fusion in cultured
mammalian cells. Transient expression of recombinant Mfn2 (visualized in
green in contrast to untransfected cells; mitochondria visualized by anti-
cytochrome c staining) results in altered mitochondrial morphology showing
increased length and connectivity as well as different degrees of fusion
according to the transiently expressed Mfn2 levels.
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spermatids giving rise to a high number of unfused mitochon-
dria. The resulting male sterility clearly demonstrates, that Fzo
is required for developmentally regulated fusion of mitochon-
dria. Genetic and biochemical analysis in fly and yeast revealed
that Fzo/Fzo1p is an evolutionary conserved transmembrane
GTPase of the mitochondrial outer membrane, which controls
fusion in a GTPase dependent manner [8,9]. In addition to this
particular case of mitochondrial fusion during Drosophila
spermatogenesis, the fusion of mitochondria is thought to be
required for a wide range of cellular functions. It has been
hypothesized that this process supports efficient energy transfer
into subcellular compartments [10], maintains inheritance of the
mitochondrial genome in yeast [9,11] or serves as protective
mechanism in mammalian cells to cope with frequent
mitochondrial heteroplasmy (i.e., mitochondria with either
mutant or wild type mtDNA) [12,13]. Concomitantly, mito-
chondrial fusion is the counterpart of mitochondrial fragmen-
tation or fission, a process involved in the maintenance of
mitochondrial morphology as part of an underlying equilibrium
of fusion and fission events [14]. In this review, I will
summarize our current understanding of how mammalian
homologues of this class of proteins, referred to as the
Mitofusins, contribute to the maintenance of mitochondrial
morphology. In addition, I will discuss recent results, opinions
and observations regarding “the many faces” of Mitofusin
function and dysfunction in health and disease.
2. Mitofusin structure and function
Mitofusins (Mfn) represent a class of highly conserved
mitochondrial transmembrane GTPases homologues found in
budding yeast [9], C. elegans, Drosophila and mammals [8,15–
18]. Two functional homologues of the Drosophila Fzo class of
mitochondrial GTPases have been found and characterized in
mammals. The two mammalian Mitofusins, Mfn1 and Mfn2,
share the same structural motifs found in all members of this
evolutionary conserved class of mitochondrial GTPase (Fig. 1).
These proteins are characterized by the presence of a highly
conserved GTPase domain in the N-terminal half of the protein
and a bipartite transmembrane domain, which anchors the
protein to the mitochondrial outer membrane (OM). In addition,the Carboxy-terminus also carries a structurally conserved
alpha-helical region forming a coiled coil structure (also
designated heptad repeat domain, HR2), besides a second
internally located HR1 structure (Fig. 1). Structural and
biochemical studies established that both termini, containing
the GTPase and HR2 coiled coil structure, respectively, are
exposed to the cytoplasm [19,20]. This particular topology is
important for the understanding of Mitofusin function during
mitochondrial fusion (see below).
2.1. Mitofusins are mediators of mitochondrial fusion
Transient overexpression of recombinant mammalian Mito-
fusins in cell culture initially revealed their capability to trigger
uncontrolled mitochondrial fusion. When transiently expressed
in mammalian cells, both variants, Mfn1 and 2, cause the
formation of highly elongated and interconnected mitochondrial
tubules in contrast to the filamentous appearance of mitochon-
dria in untransfected cells (Fig. 2), suggesting an increase of
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network collapses to form perinuclear clusters of fused
mitochondria when very high levels of recombinant Mfn are
expressed (Fig. 2, arrowhead). The Mitofusin requirement for
the control of mitochondrial fusion, however, became more
evident with the analysis of mitochondrial morphology in Mfn-
deficient mouse embryonic fibroblasts (MEFs) derived from
knockout mice. As in the fzo1Δ mutant yeast strain [9],
knockout of both Mitofusins resulted in the formation of small,
fragmented mitochondria indicating that unopposed fission of
mitochondria occurs due to abrogated mitochondrial fusion
[21,22]. Interestingly, Mfn1 knockout cells contained short
spherical mitochondria uniform in size, while mitochondrial
morphology in knockout cells lacking Mfn2 appeared less
fragmented giving rise to larger spheres of variable size. RNAi-
mediated loss of function of rat Mitofusin homologues in cell
culture caused a similarly aberrant, but not as severe,
mitochondrial morphology phenotype [23]. The establishment
of cellular mitochondrial fusion assays by in vitro induced cell
fusion (polyethylen glycol- or HBJ-virus-mediated) of knock-
out or siRNA-treated cells bearing different fluorescently
labelled mitochondria allowed the study of mitochondrial
fusion events more closely [24–26]. This assay uncovered the
reduction in mitochondrial fusion due to loss of Mitofusins and
emphasized the need of both isotypes for the control of
mitochondrial fusion in mammalian cells. Hence, the paradigm
of an equilibrium of mitochondrial fusion and fission processes
for the maintenance of mitochondrial morphology suggested by
genetic analysis in yeast [27,28] was also proven to be a
conserved mechanism in mammalian cells.
2.2. Mitofusin GTPase function in mitochondrial fusion
Mitochondrial fusion depends on the GTPase activity of
Mitofusin proteins [8,9,21]. Interestingly, fusion requires an
active inner mitochondrial membrane potential, but occurs
independently of cytoskeletal structures such as actin and
microtubules [24–26]. Both Mitofusins exhibit GTP hydrolysis
activity [29,30] through the action of their GTPase domain. It is
noteworthy to mention, that Mfn1, however, exhibits a much
higher GTP hydrolysis activity (approximately 8-fold) than
Mfn2. In contrast, Mfn2 appears to have a higher GTP binding
activity than Mfn1 [29]. The highly conserved GTPase domain
comprises the four signature motifs G1–4, as found in other
members of the GTPase protein superfamily such as the Ras
protein [31]. These subdomains are crucial for carrying out the
binding and hydrolysis of GTP as well as release of GDP.
Therefore, specific alterations of highly conserved residues
within these motifs affect GTPase activity and consequently
mitochondrial fusion. Dependent on the site or nature of the
GTPase mutation, mutant Mfn variants with different enzymatic
properties can be obtained exhibiting altered rates of nucleotide
binding, hydrolysis, and exchange. These variants are classified
as “GTPase inactive” mostly carrying mutations in the G1
subdomain (such as the critical exchanges as hMfn1K88T and
hMfn2K109T) or as “dominant negative” resembling a loss-of-
function situation due to blocking any mitochondrial fusionactivity, and finally a “dominant active”mutant (hMfn2RasG12V)
exhibiting enhanced fusion activity [21,23,30,32–34]. Expres-
sion of GTPase-negative variants in the Mfn-knockout cells, or
by transient expression in cultured cells unravelled the necessity
for proper GTPase activity during the fusion process, since
these variants either failed to rescue loss of fusion activity in the
knockout cells or showed no effect of enhanced mitochondrial
fusion when compared to expression of GTPase-active Mfn.
Other overexpression experiments even suggested that partic-
ular mutant variants of Mfn1 and Mfn2 bearing substitutions in
the G1 or G2 motif (rMfn2K109T for G1 and hMfn1T109A for
G2) acted as dominant negative mutants causing the complete
block of mitochondrial fusion with consequent mitochondrial
fragmentation [23,33]. All these observations strongly advocate
for the critical role of the GTPase activity in controlling
mitochondrial fusion, but the mechanism by which it controls
the fusion process is still unknown. It is conceivable that
Mitofusins directly mediate the fusion, or indirectly mediate
fusion by promoting subsequent mechanistic steps during the
process. In vitro studies employing sophisticated immunopre-
cipitation and fluorescence microscopy approaches shed some
light on the function of the GTPase domain [29]. This study
demonstrated that mitochondrial membrane tethering through
Mfn interaction was directly dependent on GTP hydrolysis. In
other words, this work suggests the model by which
mitochondria become tethered through the GTPase-dependent
formation of apposing Mfn proteins (from adjacent mitochon-
dria) in trans prior to fusion. Moreover, biochemical data
further showed that Mfn1 can oligomerize in a GTPase-
dependent manner to form complexes of different sizes/
oligomeric state.
2.3. Structural aspects of GTPase function during
mitochondrial fusion
Earlier in vitro studies had already implied that Mitofusins
can form either homotypic (consisting of the same Mfn
isotypes) or heterotypic (consisting of Mfn1 and Mfn2)
interactions [21,19,29,35]. The interaction of Mitofusins is
mediated by pairing of the C-terminal coiled coil domain HR2.
Crystal structure analysis from self-associated mouse Mfn1
coiled coil complexes (Mfn1/HR2) showed that the coiled coil
domains arranged as dimeric anti-parallel helices of 95 Å in
length [19]. Similar to the GTPase-domain, the HR2 domain
appears to also be essential for the mitochondrial fusion process,
since single amino acid substitutions perturbing the formation
of the coiled coil structure neither rescued the mutant phenotype
in Mfn1−/− null MEFs nor led to fused mitochondria in the
PEG-cell fusion assay [21]. Interestingly, the formation of
homotypic Mfn1-complexes was not abolished when an N-
terminally truncated version of Mfn1 lacking the GTPase
domain was expressed in stably transduced NIH3T3 fibroblasts.
In this case, mitochondrial clusters were formed, indicating a
GTPase-independent interaction, but not fusion of mitochon-
dria. Similar observations were also made with N-terminally
truncated variants of Mfn2 [20,30]. However, mutant Mfn1
variants of the GTPase-lacking derivative with residue
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aggregate suggesting that membrane tethering was abolished.
This observation is in contrast to the GTPase-requirement for
the tethering of mitochondrial membranes. Therefore, this
structural information along with the above discussed
molecular data indicate that mitochondrial fusion occurs as
a multi-step process starting with a tethering step of apposing
mitochondrial membranes by Mfn dimerization, followed by a
presumably GTPase-induced docking step to bring the
membranes of adjacent mitochondria in close proximity
before the final fusion of the bilayers occurs. In agreement
with both findings, it is conceivable that the GTPase cycle
promotes a structural modulation of the protein making the
coiled coil more accessible.
Alternatively, for human Mfn2, a signalling function has
been proposed. A GTPase-defective mutant, referred to as
hMfn2RasG12V, bears amino acid substitutions within the
phosphate-binding loop (P-loop) structure of the GTPase [36].
This particular Mfn2 mutant should be constitutively active due
to its inability to hydrolyze GTP owing to the capability of
nucleotide binding and exchange, but not of hydrolysis [30].
When transiently expressed in cultured cells, this GTPase-
mutant variant accelerates mitochondrial fusion as assessed by
the PEG cell fusion assay. It was therefore proposed that
hydrolysis activity might be independent for fusion favoring the
idea that Mfn2 GTPase activity regulates signalling for
initiation rather than execution of mitochondrial fusion.
2.4. Mfns role in the coordination of IM fusion
The current model is far from complete and only a
simplified view of the first steps occurring on the mitochon-
drial outer membrane during fusion. Hence, future work needs
to elucidate what happens beyond the early steps of outer
membrane tethering and docking, and how exactly the GTPase
cycle is coupled to the single fusion stages. Furthermore, it
needs to be clarified how the mixing of the inner membrane is
coordinated and exerted. The involvement of the inner
membrane in Mitofusin mediated fusion has not been dissected
in the mammalian system, whereas in vitro studies in yeast
have provided some insight into that process [37,38].
Consistent with the finding in yeast that the loop domain,
spanning both TM domains (exposed to the inner membrane
space: IMS-domain) contributes to mitochondrial fusion [39],
an Mfn2-mutant variant of the “IMS-domain” (Mfn2W6321P)
affects fusion but becomes ineffective when the GTPase
domain was activated (Mfn2RasG12V) [30]. Certainly, other
proteins must participate in the fusion process, in particular
components of the inner membrane. One candidate for this
coordinative interaction appears to be OPA1, another mito-
chondrial GTPase (see also review from P. Belenguer in this
issue), residing as a peripheral protein of the inner mitochon-
drial membrane in the IMS [40–45]. OPA1 has been identified
as another critical factor governing mitochondrial fusion
[35,46]. Interestingly, in yeast the UGO1 protein bridges the
interaction between the Fzo1p and the yeast OPA1 homologue
Mgm1p. However, a mammalian orthologue has not beenidentified so far (summarized in [14]). Again, the mechanistic
interplay and regulation of these two mediators of mitochon-
drial fusion is presently unknown and remains to be elucidated.
A recent publication discusses an essential contribution of
other Mitofusin domains (especially a conserved region at the
N-terminus far upstream of the GTPase domain) to mitochon-
drial fusion besides the GTPase and coiled coil domains
proposing a coordinated interplay of both termini [47]. Finally,
the molecular studies established mitochondrial fusion to be
different from other characterized membrane fusion mechan-
isms such as viral or SNARE-mediated fusion [48].
3. Mfn1 versus Mfn2: Do they play different or redundant
functions?
There is no doubt that both Mitofusin proteins can mediate
mitochondrial fusion. Nevertheless, the question regarding a
functional difference or redundancy of these two proteins
remains to be clarified. Although both proteins share many
structural and functional similarities, an increasing amount of
evidence points to isotype specific roles and activities in
mitochondrial biology. Mammalian Mitofusins are ubiquitously
expressed but show differences in expression levels for certain
tissues [20,23,33]. Some reports discuss a predominant
expression of Mfn2 in heart and skeletal muscle [32,33] in
contrast to the generally expressed Mfn1 [33], or even suggest a
developmentally regulated expression during myotube forma-
tion [32]. In addition, contradictory expression data on both the
expression levels and protein sizes for the rat Mitofusins have
been reported [22,23,32]. As already outlined above, the
distinct mitochondrial morphology phenotypes observed in
Mfn1 and Mfn2 knockout MEFs [21,35] indicate a different
behaviour of both protein variants. This observation is
consistent with results based on depletion of both Mitofusins
by RNAi in HeLa cells [23]. Nevertheless, differences in
mitochondrial fusion between both isotypes exist, when
analyzed in knockout cells by the PEG cell fusion assay. In
this assay, after fusion of Mfn1-deficient cells mitochondria in
some polykaryons stayed separate and did not intermix
(“sectoring effect”) most likely due to impaired motility. In
contrast, mitochondria in fused Mfn2-deficient polykaryons
were distributed throughout the cell. Hence, the studies
performed with knockout mouse fibroblasts indicated that
Mfn1 plays a more prominent role in mitochondrial fusion,
since loss of Mfn1 function resulted in more pronounced
severity of fusion deficiency [35]. Importantly, Mfn1 and Mfn2
deficiency in these knockout cells can be rescued by expression
of the single Mitofusin variant independently of the Mfn-mutant
background, but with significant differences in rescuing
efficiency [21]. Accordingly, knockout mutant mice exhibit
isotype-specific differences in terms of severity of the
embryonic lethal phenotypes. While Mfn1 was similarly
efficient in rescuing the Mfn1 and Mfn2 phenotype, Mfn2
was only to some extent able to restore mitochondrial
morphology in Mfn1-mutant cells [21]. This observation can
be explained by differences in mitochondrial fusion activity
between Mfn1 and Mfn2. Biochemical studies on recombinant
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binding and hydrolysis properties of both isotypes as discussed
in Section 2.2 [29,30].
A similar picture emerges from overexpression experiments
with recombinant protein variants from Mfn1 and Mfn2 in
cultured cells pointing to isotype-specific alterations in
mitochondrial morphology [23,33,34]. Isotype-specific mode
of action for both Mitofusin proteins was uncovered with regard
to their cooperation with OPA1, another mitochondrial GTPase
implicated in the control of mitochondrial fusion. OPA1
function is absolutely required for mitochondrial fusion, but
surprisingly, it relies on Mfn1 but not Mfn2 for fusion [46]. In
summary, these results provide compelling evidence that both
Mitofusins despite their mitochondrial fusion activity, behave in
a different and isotype-specific way. Future research has to
decipher the functional and structural differences with regard to
their effects on mitochondrial and cellular physiology.
4. Mitofusin-2 dysfunction in the CMT2A peripheral
neuropathy disease
Impairment of mitochondria has disastrous consequences
evident in many human diseases like diabetes, various cancers,
encephalomyopathies and neuropathies. Human genetics espe-
cially suggests a strong tie between mitochondrial dysfunction
and many neurodegenerative disorders including Huntington's
disease, forms of Parkinson's disease, Alzheimer disease,
hereditary spastic paraplegia, and Friedreich's ataxia (for
review, see [49]). Interestingly, independent investigations
uncovered a link between mutations in the human Mfn2 gene
and the onset of Charcot–Marie–Tooth neuropathy type 2A
(CMT2A) underscoring the critical role of Mitofusins and the
control of mitochondrial fusion in maintaining cell function
[50–52].
4.1. Charcot–Marie–Tooth neuropathy
Charcot–Marie–Tooth disease (CMT) comprises axonal
and demyelinating forms of hereditary motor and sensory
neuropathy (HMNS, summarized in [53], also see http://
www.neuro.wustl.edu/neuromuscular/time/hmsn.html).
This inherited neurodegenerative disorder is clinically
characterized by the gradually progressing degeneration of
peripheral neurons (such as ganglion cells). CMT comprises a
class of heterogeneous forms depending on the affected
neuronal structure such as the myelin sheath (CMT1:
impairment of Schwann cell–axonal interactions due to
autosomal dominant inherited demyelization) or the axon itself
(CMT2A-G: autosomal dominant, CMT4 autosomal recessive),
which can only be distinguished by electrophysiological
features. The CMT2 type is linked to eight different loci [50]
and references therein) with CMT type 2Amapped to the 1p35–
36 locus on chromosome 1 (http://www.ncbi.nlm.nih.gov/
entrez/dispomim.cgi?id=609260). The pathology of the
CMT2-forms is primarily characterized by the degeneration of
distal axonal parts at early stages of disease, finally resulting in
the degeneration of the neurons themselves. As a consequence,the disease becomes clinically apparent by a loss of neuronal
sensation owing to low neuronal conduction amplitudes (in
contrast to low conduction velocities in CMT1) as well as
paralysis of distal muscle groups of the extremities caused by
muscle atrophy. CMT is usually accompanied by foot
abnormalities, such as a high arch or flexed toes.
4.2. Mfn2 mutations and CMT2A
Genetic analysis of several families has suggested that
mutations in the human Mfn2 gene are primarily responsible for
the onset of CMT2A [50–52]. All three studies report the
identification of mutations accumulating (with one exception)
within exons encoding the GTPase domain or coiled coil structures
of Mfn2. Remarkably, the vast majority of the described 17
different mutations (see Note added in proof) reside within GTPase
domain encoding sequences, with one particular mutation in two
cases causing a change in the P-loop G1 subdomain (T105M), a
highly conserved region among all described Mitofusin homo-
logues. Instead, another hotspot for mutations is in close proximity
to the G4 subdomain. Interestingly, all mutations described are
missense mutations. These observations imply impaired mito-
chondrial fusion in axons of peripheral neurons of CMT2A
patients and underscore the relevance of the coiled coil structure
and in particular the GTPase domain.
Initially, mutations in a nearby locus, encoding a KIF1B
kinesin isotype were proposed to be the cause for CMT2A.
KIF1Bβ is a kinesin microtubule motor protein specifically
implicated in the anterograde (i.e., synapse-directed) transport
of mitochondria [54]. Therefore, the disruption of axonal
transport was hypothesized as the underlying cellular mecha-
nism for CMT2A disease development, consistent with the
observation that mutant dynactin, another motor-associated
protein, also caused motor neuron disease [55]. In contrast to
multiple mutations found in Mfn2 in several pedigrees, the
KIF1Bβ mutation was found in only one family, supporting the
idea that a mutated Mfn2 gene is the common cause for
CMT2A.
4.3. Speculations on Mfn2 dysfunction in CMT disease
The perspective that impaired axonal transport is one of the
common causes for axonal degeneration [53] needs to be
revisited or expanded. It is conceivable that Mfn2 dysfunction
might interfere with proper mitochondrial transport along the
axons leading to energy deprivation at distant axonal sites. This
is supported by the fact that mitochondria lacking Mfn function
exhibit altered mobility in knockout cells [21]. However, to
date, no experimental evidence suggests Mfns to be directly
involved in mitochondrial motility or transport. Especially for
neurons, it is believed that mitochondria prefer to aggregate in
regions with high energy demands [56]. Nevertheless, it is
likely that mitochondrial fusion processes are contributing to
the organelle's trafficking in order to accommodate the specific
delivery and positioning of mitochondria and by setting up
elongating mitochondrial cables or filaments to reach sites with
high energy demands. The distribution of mitochondria in
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action of mitochondrial fission/fusion components [57].
Alternatively, impaired mitochondrial energy metabolism
due to Mfn2 dysfunction can account for neuronal degeneration.
Recent reports discuss the direct impact of Mfn2 function on the
maintenance of the cell's energy balance [32,58,59]. In more
detail, levels in Mfn2 apparently affect mitochondrial energy
metabolism either by fusion control or by a separate, fusion-
independent mechanism. Changes in levels of Mfn2 not only
altered mitochondrial morphology, but also influence the
OXPHOS system. Fundamentally, oxidation processes, for
example, membrane potential as well as oxidative phosphory-
lation appeared to be suppressed due to reduced expression of
nuclear encoded components of the respiratory chain at low
levels of Mfn2 protein. Conversely, increased levels of Mfn2 in
turn seemed to stimulate the expression of OXPHOS subunits
thereby enhancing mitochondrial metabolic activity [58]. Since
these results were obtained transiently in vitro with cultured
muscle cells by recombinant molecular means it remains to be
clarified whether or not similar effects can be observed in
neuronal cells. Moreover, mutational analysis will be invaluable
in unraveling the putative link between mitochondrial fusion
and the bioenergetics-modulating capabilities of the Mfn2
protein, especially in the context of the disease causing Mfn2-
mutations. Furthermore, impaired Mfn2 function might also
make cells more susceptible to free radical damage as metabolic
stress factor. In cell culture experiments Mfn2 apparently
protects cells from radical damage and in turn apoptosis [30].
So far, the mitochondrial morphology in the diseased cells of
CMT2A patients has not been evaluated in order to figure out
whether loss in Mfn2 function leads to fragmentation and in
turn neurodegeneration [60]. Surprisingly, mutations in the
Mfn2 isotype only affect peripheral neurons. Hence, CMT does
not impair most other physical functions, including for example
the cardiovascular system. This raises the question of why in
particular neuronal cells become affected, but not other organs,
like for example, liver or heart and skeletal muscle known to
require high energy expenditure and mitochondrial activity.
Especially considering the Mfns putative role in apoptosis
control, it cannot be ruled out that loss of Mitofusin function
makes neuronal cells more susceptible to apoptosis, a critical
determinant for neurodegeneration (see also discussion by
[61]).
Remarkably, mutations in the GDAP1 (Ganglioside-induced
differentiation associated protein 1) gene were found in patients
with another form of CMT [62]. GDAP1 turned out to be a
mitochondrial protein expressed in neuronal and glia cells,
which also appears to contribute to the control of mitochondrial
dynamics [63]. In addition, the gene encoding the mitochondrial
fusion GTPase OPA1 has been linked to the autosomal
dominant optic atrophy (ADOA), another neurodegenerative
disease marked by degeneration of retinal ganglion cells [64].
These results clearly demonstrate the physiological impact of
altered mitochondrial dynamics on the physiology of the organ.
Nevertheless, the molecular mechanism underlying the cause of
Mfn2 dysfunction for neuronal cell degeneration needs to be
addressed. Mutations in the human Mfn1 gene have not beenidentified or linked to any known inherited human disease yet,
so that its putative pathophysiological effect is still obscure.
5. Speculations about diverse cellular functions of
Mitofusins in health and disease
Mitochondrial dysfunction is directly associated with
pathological conditions and disease in human and mammals
[65–67]. The potential impact of Mitofusin dysfunction on
mitochondrial metabolism and physiology has been discussed
above in the context of the onset of neurodegenerative diseases.
5.1. Mitofusin knockout phenotypes
Changes in levels of both Mitofusins affect mitochondrial
morphology due to an imbalance of mitochondrial fusion and
fission events. Mitofusins can only compensate to some
extent for each other's loss in mouse Mfn-knockout cells, so
that a little mitochondrial fusion activity is retained. By
contrast, the total loss of Mitofusin-dependent mitochondrial
fusion activity leads to mitochondrial dysfunction in Mfn-
double mutant MEF cells. The Mfn-deficient cells are
characterized by a loss of the mitochondrial membrane
potential, inhibition of cell proliferation, and defects in
mitochondrial respiration [35], whereas all these cellular
functions are retained in cells lacking only one Mitofusin
isotype. Therefore, it has been reasoned that the activity of a
single Mitofusin provides sufficient mitochondrial fusion to
escape major cellular deficits. Consequently, MEFs deficient
in either Mfn1 or Mfn2 do not exhibit severe cellular defects
(besides some “stochastic loss” of membrane potential in
individual mitochondria). The experiments with Mfn-double
mutant cells also corroborate the requirement of mitochon-
drial fusion for the maintenance of critical mitochondrial
function. Hence, impaired mitochondrial physiology is likely
to be directly associated with the loss of mitochondrial
fusion, but not as an indirect result of uncontrolled
mitochondrial fission due to lack of Mitofusin activity. In
this light it is surprising to observe a clear influence in cells
with reduced levels of Mfn2 as discussed above, although
Mfn1-fusion activity is still present. Therefore, even little
Mitofusin dysfunction becomes pathophysiologically apparent
when occurring in its developmental and physiological
context in vivo. This idea becomes evident when looking
at Mfn-knockout mice. Whereas mice heterozygous for both
Mfn1- or Mfn2-knockout alleles are fully viable, homozy-
gous mutant mice show embryonic lethality at midgestation
stage. Interestingly, embryos homozygous for the Mfn1-null
allele show a stronger delay in development with more
severe malformation in contrast to Mfn2-null homozygotes.
Strikingly, the Mfn2-null mutant embryos develop normally
until defects of the fetal placenta become apparent. These
observations once again demonstrate that both Mitofusin
isotypes exhibit certain functional differences.
Considerable progress has been made in deciphering
Mitofusins physiological and cellular function. As depicted in
Fig. 3, Mitofusins are implicated in various cellular functions,
Fig. 3. Summary of the hypothesized functions of mammalian Mitofusin
proteins. Apart from Mitofusins role in mediating mitochondrial morphology
and dynamics, Mitofusins (particularly Mfn2) might play additional roles in
cellular signalling and apoptosis control. Effects on mitochondrial metabolism
may be a consequence of fusion, but might also be controlled directly by
currently unknown mechanisms.
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associated with the mitochondrial fusion activity in the context
of disease development.
5.2. Mfn2 and type 2 diabetes mellitus
The type 2 diabetes mellitus is characterized by an insulin
resistance, which affects the physiology of the skeletal muscle.
In addition, obesity is a major risk factor of type 2 diabetes. It
has been proposed that an altered mitochondrial metabolism
(reduced glucose and fatty acids oxidation for example) also
accounts for insulin resistance in target tissues. As outlined
above, initial studies reported altered glucose oxidation upon
changes in Mfn2 expression levels as assessed by different in
vitro and in vivo model systems [32,59]. Recent investigations
aimed to confirm this correlation by analyzing the effect of
different physiological and pathophysiological conditions such
as obesity (and its molecular mediators TNFα and interleukin-
6), diabetes, insulin, exercise, or weight loss on Mfn2 gene
expression by mRNA quantification in human skeletal muscle
or cell culture, respectively. Interestingly, all of these conditions
appeared to modulate the expression of the Mfn2 gene in a
positive (up-regulation after exercise and weight loss) or
negative manner (down-regulation under obese and diabetic
conditions and after exposure to TNFα/IL-6) qualifying the
Mfn2 gene as a good molecular candidate to be involved in the
altered mitochondrial metabolism and finally contributing to
insulin resistance [58,60,68]. Hence, these studies suggest a
putative role of Mitofusins (Mfn2) in integrating physiological
parameters or signals for mitochondrial function, metabolism,
and biogenesis. Notably, regarding the discussed signalling
circuits, Mfn2 expression was shown to become activated by
the action of the PCG-1α and ERRα transcriptions factors in
muscle cells after acute exercise [68,69]. Indeed, it will be
exciting to see in the future how these changes in Mfn2
expression correlate with altered mitochondrial architecture indiseased or stimulated tissues, and whether correction of these
alterations can counteract pathological conditions.
5.3. Ras-signalling and implications for atherosclerosis and
hypertension
Concerning the effect of changes in Mfn2 expression on the
cells or organ's physiology, another group reported the role of
rat Mfn2 (rMfn2) in controlling signal transduction with
implications for cardiovascular diseases such as hypertension
or atherosclerosis [22,70]. In this case, rMfn2 is attributed a
distinct role as a modulator of signal transduction independent
from its mitochondrial function. In a rat in vivo model for
hypertension due to hyperplasia of vascular smooth muscle cells
(VSMCs), rat Mfn2 (also referred as rHSG for rat hyperplasia
suppressor gene) was identified as a potential regulator of
VSMC proliferation [22,70]. While downregulated in prolifer-
ating VSMCs, overexpression of rMfn2 interfered with the cell
cycle of VSMC by abrogating the Ras-signalling pathway. The
Ras-GTPase is a pivotal integrator of growth factor signalling
for stimulation of proliferation. The rMfn2 gene appeared to
inhibit the ERK1/2 activation signal independently of its
mitochondrial localization through interaction with Ras result-
ing in a G0/G1 cell cycle arrest. Furthermore, rMfn2 was
proposed to regulate VSMC proliferation in vivo in response to
arterial injury. Conversely, in an animal model of atheroscle-
rosis the arterial VSCM proliferation resulted in the suppression
of rMfn2 expression implicating rMfn2 dysregulation as a
possible contributor to proliferative cardiovascular disorders.
Strikingly, Mfn2-deficient MEFs have no (positive) apparent
effect on proliferation. The Mfn-double mutant instead showed
severe growth defects, but no stimulation of proliferation [35].
Details of this inconsistency remain to be clarified, especially
with respect to possible contributions to other diseases with
derailed proliferation such as cancer.
5.4. Mitofusin and the control of apoptosis
Mitochondria play a pivotal role in coordinating programmed
cell death. The release of several proteins, such as
cytochrome c, AIF, Smac/Diablo, from the mitochondrial
intermembrane space into the cytoplasm is a hallmark event
in the onset of cell death resulting in the activation of the
apoptotic cascade [71]. The discovery of Drp1-mediated
mitochondrial fission as the initiating step of OM permeabi-
lization shifted our perspective on the remodelling process of
mitochondrial morphology during apoptosis [72–74]. With
the onset of apoptosis, pro-apoptotic Bax accumulates in a
spatial manner on the OM at the prospective mitochondrial
fission sites. Moreover, Drp1 translocates from the cytoplasm
to these fission sites, where later mitochondrial fragmentation
occurs [72]. Interestingly, it turned out that Mfn2 is also
present at these fission sites together with Bax and Drp1,
suggesting a possible counteracting, regulatory function of a
Mitofusin in the process [75]. A sophisticated microscopic
approach, however, revealed that mitochondrial fusion
becomes inhibited when activated Bax coalesces into these
497A. Santel / Biochimica et Biophysica Acta 1763 (2006) 490–499particular foci on mitochondrial the OM [76]. Other studies
suggest an active role of Mitofusins in inhibiting apoptosis. In
transient expression experiments after staurosporine induced
apoptosis, Mfn2 and its variant Mfn2RasG12V (“activated
Mfn2”) inhibited the activation of Bax and the release of
cytochrome c and protected from cell death [30,77].
Conversely, siRNA-mediated transient loss of function of
Mfn1/2 led to increased cell death. These findings are
consistent with the observation that loss of mitochondrial
fusion after downregulation of the other fusion factor OPA1
results in apoptosis [43].
6. Perspectives
Mitochondria vary in size and shape from cell to cell, and
are even morphologically and functionally heterogeneous
within a single cell [78]. Mitochondrial fusion presents one
key process in the control of mitochondrial morphology. The
biological significance of these dynamic changes in the
organelle's shape or structure and the exact mechanisms
underlying these phenomena still remain relatively obscure.
Especially with respect to specificity and physiological role of
Mitofusin proteins in vivo, many unanswered questions
remain to be addressed. Even less is known about the
proteins or cellular components mediating and controlling this
fusion process. More information is needed on the function of
this novel intracellular fusion phenomenon and on how
Mitofusins are integrated into the mitochondrial dynamics-
controlling process. What intracellular signals induce mito-
chondrial shape changes? How is mitochondrial morphology
integrated into cell function with respect to specificity or
timing during cell division, differentiation and development?
Do both Mitofusins cooperate in vivo or do they fulfill their
functions separately? All these questions present a challenge
for future investigations.
Note added in proof
While this manuscript was in the reviewing process another
publication describes additional mutations in the human Mfn2
gene resulting in axonal neuropathy with optic atrophy:
Zuchner et al. [79].
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